Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics

Acquisition of the GMP biologics manufacturing facility expands Xcellon’s integrated capabilities from discovery through clinical supply and strengthens U.S. biomanufacturing

Acquisition of the GMP biologics manufacturing facility expands Xcellon’s integrated capabilities from discovery through clinical supply and strengthens U.S. biomanufacturing

Go to Source